# India Infoline Result Update <br> Procter \& Gamble Hygiene \& Healthcare Ltd (9M F6/07) <br> CMP: Rs769 <br> May 10, 2007 

$>$ Net sales decline $9 \%$ yoy to Rs4.1bn sans contract manufacturing operations. Core health $\mathbb{\&}$ hygiene business registered strong 15\% yoy growth.
$>$ OPM expanded by 610bps to $\mathbf{2 9 . 1 \%}$ sans low margin detergent business. Increase in adspend and staff cost restrict further margin expansion.
> Adjusted net profit decreased by $\mathbf{1 7 \%}$ yoy to Rs772mn partly due to lower other income.

Financials Highlights

| Period to | $\mathbf{0 3 / 0 7}$ | $\mathbf{0 3 / 0 6}$ Growth |  | $\mathbf{0 3 / 0 7}$ | $\mathbf{0 3 / 0 6}$ Growth |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| (Rs $\mathbf{~ m n}$ ) | $\mathbf{( 3 )}$ | $\mathbf{( 3 )}$ | $\mathbf{( \% )}$ | $\mathbf{( 9 )}$ | $\mathbf{( 9 )}$ | $\mathbf{( \% )}$ |
| Gross sales | 1,253 | 1,153 | 8.7 | 4,264 | 4,835 | $(11.8)$ |
| Excise duty | $(24)$ | $(25)$ | $(1.6)$ | $(124)$ | $(296)$ | $(58.2)$ |
| Net Sales | 1,229 | 1,129 | 8.9 | 4,140 | 4,538 | $(8.8)$ |
| Expenditure | $(900)$ | $(861)$ | 4.5 | $(2,937)$ | $(3,495)$ | $(16.0)$ |
| Operating profit | 329 | 268 | 22.9 | 1,203 | 1,043 | 15.3 |
| Other income | 34 | 112 | $(69.6)$ | 108 | 213 | $(49.4)$ |
| Interest | 0 | 0 | - | $(0)$ | $(1)$ | $(90.9)$ |
| Depreciation | $(27)$ | $(16)$ | 70.4 | $(66)$ | $(58)$ | 14.1 |
| PBT | 336 | 364 | $(7.7)$ | 1,245 | 1,198 | 4.0 |
| Tax | $122)$ | $(98)$ | 23.8 | $(366)$ | $(342)$ | 7.2 |
| PAT | 214 | 265 | $(19.3)$ | 879 | 856 | 2.7 |
| Prior period items | 0 | 0 | - | $(107)$ | 73 | - |
| APAT | 214 | 265 | $(19.3)$ | 772 | 930 | $(17.0)$ |
| OPM (\%) | 26.7 | 23.7 | - | 29.1 | 23.0 | - |
| Equity | 325 | 325 | - | 325 | 325 | - |
| Annualized EPS (Rs) | 26.4 | 32.7 | - | 31.7 | 38.2 | - |
| P/E (x), CMP - Rs769 | 29.1 | - | - | 24.3 | - | - |

## Health \& hygiene business records strong 15\% growth

During the nine months ended March 2007, Procter \& Gamble Hygiene \& Healthcare Ltd (PGHH) registered a decline of $8.8 \%$ yoy (sans contract-manufacturing operations) in topline at Rs 4.1 bn . Revenues from core Health \& Hygiene segment recorded a strong $14.6 \%$ yoy growth. Feminine Hygiene business registered $22.6 \%$ yoy growth at Rs 2.1 bn driven by strong growth in Whisper Choice (low priced brand) and Whisper Ultra. The topline growth could have been higher but for the lower revenue growth of $7.9 \%$ yoy (at Rs 2 bn ) in the healthcare products segment.

## Margins expand sharply, sans low margin detergent business

Operating margins for the period expanded by 610 bps to $29.1 \%$ aided by a sharp decline $(25 \%$ of net sales against $35.4 \%$ of net sales during $9 \mathrm{M} \mathrm{F6} / 06$ ) in raw material cost (on account of discontinuation of low margin detergent manufacturing business). Higher adspend ( 240 bps ) and staff ( 120 bps ) cost restricted further margin expansion. The company has paid royalty of Rs 207 mn ( $5 \%$ of health \& hygiene revenues) compared to Rs 186 mn paid during Jul'06Mar'07.

Cost Analysis

| Period | $\mathbf{0 3 / 0 7}$ | $\mathbf{0 3 / 0 6}$ | Inc/Dec | $\mathbf{0 3 / 0 7}$ | $\mathbf{0 3 / 0 6}$ | Inc/Dec |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| As a \% of sales | $\mathbf{( 3 )}$ | $\mathbf{( 3 )}$ |  | $\mathbf{( 9 )}$ | $\mathbf{( 9 )}$ |  |
| Raw Material | 29.0 | 22.1 | 7.0 | 25.0 | 35.4 | $(10.4)$ |
| Staff | 6.4 | 5.8 | 0.6 | 6.9 | 5.7 | 1.2 |
| Advertising | 11.4 | 11.8 | $(0.4)$ | 11.5 | 9.2 | 2.4 |
| Royalty | 4.5 | 4.9 | $(0.3)$ | 5.0 | 4.1 | 0.9 |
| Other expenditure | 21.9 | 31.7 | $(9.8)$ | 22.6 | 22.7 | $(0.1)$ |

## Net profit down 17\% yoy

Pretax profit increased by $4 \%$ yoy to Rs 1.2 bn mainly due to lower other income (Rs 108 mn compared to Rs 213 mn in 9 M F6/06) and higher depreciation cost. Effective tax rate was at $29.4 \%$ resulting in a tax outgo of Rs 366 mn . Net profit increased marginally by $2.7 \%$ yoy to Rs 879 mn . Adjusted net profit after extraordinary items of Rs 107 mn on account of provision for prior years taxation decreased by $17 \%$ yoy to Rs 772 mn translating into an annualized EPS of Rs31.7.

## Quarterly performance

PGHH registered $8.9 \%$ yoy (sans contract-manufacturing operations) growth in topline at Rs 1.2 bn during Q3 F6/07. Feminine Hygiene segment registered strong 20.3\% yoy growth at Rs713mn driven by strong growth in Whisper Choice (low priced brand) and Whisper Ultra. Healthcare products segment however witnessed decline in revenues by $3.8 \%$ yoy to Rs 511 mn . Operating margins for the quarter expanded by 310 bps (down by 680 bps qoq) to $26.7 \%$ aided by 980 bps drop in overhead cost. The company has paid royalty of Rs56mn ( $4.5 \%$ of health \& hygiene revenues) compared to Rs55mn paid in Q3 F6/06. Higher raw material cost (700bps) restricted further margin expansion. Net profit decreased by $19.3 \%$ yoy to Rs 214 mn , mainly due to lower topline growth on account of decrease in healthcare revenues.

## Outlook

Sans transfer of contract manufacturing business to $100 \%$ subsidiary, Procter \& Gamble Home Products Ltd, the listed entity is now focused only on the Health \& Hygiene segments. The feminine hygiene business has picked up pace aided by continuing growth in Whisper Ultra and low priced variants like Whisper Maxi \& Whisper Choice.

Sans contract manufacturing (a low margin, low ROCE business) PGHH's margins have also been positively impacted. The company has set up two new health care plants in Baddi with an investment of Rs600mn, to meet the increasing demand for its products. With the additional revenues from these plants, which have commenced production during Q2 F6/07, we expect the overall profitability to improve going forward. The company will continue to produce the feminine hygiene products at its Goa facility.

[^0]
[^0]:    Published in May 2007. © India Infoline Ltd 2007-08.
    This report is for information purposes only and does not construe to be any investment, legal or taxation advice. It is not intended as an offer or solicitation for the purchase and sale of any financial instrument. Any action taken by you on the basis of the information contained herein is your responsibility alone and India Infoline Ltd (hereinafter referred as IIL) and its subsidiaries or its employees or directors, associates will not be liable in any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained herein, but do not represent that it is accurate or complete. IIL or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this publication. The recipients of this report should rely on their own investigations. IIL and/or its subsidiaries and/or directors, employees or associates may have interests or positions, financial or otherwise in the securities mentioned in this report.

